1
|
Vankadara S, Ke Z, Wang S, Foo SY, Gunaratne J, Lee MA, Koh X, Chia CSB. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines. Chem Biol Drug Des 2024; 103:e14516. [PMID: 38618710 DOI: 10.1111/cbdd.14516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 02/27/2024] [Accepted: 03/16/2024] [Indexed: 04/16/2024]
Abstract
Ovarian cancer is the most deadly female gynaecological malignancy in developed countries and new treatments are urgently needed. The luteinising hormone releasing hormone (LHRH) peptide drug conjugate Zoptarelin doxorubicin is one such potential new drug modality that entered clinical trials for treating LHRH receptor-positive gynaecological cancers. However, development stopped after disappointing Phase 3 results in 2017. We believe the lack of efficacy was due to linker instability and payload potency. In this work, we replaced its linker-toxin with vedotin (MC-VC-PABC-MMAE), yielding the novel peptide drug conjugate D-Cys6-LHRH vedotin. A GI50 and cell specificity comparison against cancerous and non-cancerous ovarian cell lines showed significantly superior bioactivity and selectivity over Zoptarelin doxorubicin (GI50 4 vs. 453 nM) and other chemotherapeutic drugs used for treating ovarian cancers. Our results suggest D-Cys6-LHRH vedotin can potentially be used as a treatment for ovarian cancer.
Collapse
Affiliation(s)
- Subramanyam Vankadara
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| | - Zhiyuan Ke
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| | - Sifang Wang
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| | - Sin Yun Foo
- Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| | - Jayantha Gunaratne
- Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
- Department of Anatomy, Yong Loo Lin School of Medicine, 4 Medical Drive, MD10, National University of Singapore, Singapore, Republic of Singapore
| | - May Ann Lee
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| | - Xiaoying Koh
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| | - C S Brian Chia
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
| |
Collapse
|
2
|
Loh YY, Anantharajan J, Huang Q, Xu W, Fulwood J, Ng HQ, Ng EY, Gea CY, Choong ML, Tan QW, Koh X, Lim WH, Nacro K, Cherian J, Baburajendran N, Ke Z, Kang C. Identification of small-molecule binding sites of a ubiquitin-conjugating enzyme-UBE2T through fragment-based screening. Protein Sci 2024; 33:e4904. [PMID: 38358126 PMCID: PMC10868430 DOI: 10.1002/pro.4904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 01/03/2024] [Accepted: 01/04/2024] [Indexed: 02/16/2024]
Abstract
UBE2T is an attractive target for drug development due to its linkage with several types of cancers. However, the druggability of ubiquitin-conjugating E2 (UBE2T) is low because of the lack of a deep and hydrophobic pocket capable of forming strong binding interactions with drug-like small molecules. Here, we performed fragment screening using 19 F-nuclear magnetic resonance (NMR) and validated the hits with 1 H-15 N-heteronuclear single quantum coherence (HSQC) experiment and X-ray crystallographic studies. The cocrystal structures obtained revealed the binding modes of the hit fragments and allowed for the characterization of the fragment-binding sites. Further screening of structural analogues resulted in the identification of a compound series with inhibitory effect on UBE2T activity. Our current study has identified two new binding pockets in UBE2T, which will be useful for the development of small molecules to regulate the function of this protein. In addition, the compounds identified in this study can serve as chemical starting points for the development of UBE2T modulators.
Collapse
Affiliation(s)
- Yong Yao Loh
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Jothi Anantharajan
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Qiwei Huang
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Weijun Xu
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Justina Fulwood
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Hui Qi Ng
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Elizabeth Yihui Ng
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Chong Yu Gea
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Meng Ling Choong
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Qian Wen Tan
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Xiaoying Koh
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Wan Hsin Lim
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Kassoum Nacro
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Joseph Cherian
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Nithya Baburajendran
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - Zhiyuan Ke
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| | - CongBao Kang
- Experimental Drug Development Centre (EDDC)Agency for Science, Technology and Research (A*STAR)SingaporeSingapore
| |
Collapse
|
3
|
Anantharajan J, Tan QW, Fulwood J, Sifang W, Huang Q, Ng HQ, Koh X, Xu W, Cherian J, Baburajendran N, Kang C, Ke Z. Identification and characterization of inhibitors covalently modifying catalytic cysteine of UBE2T and blocking ubiquitin transfer. Biochem Biophys Res Commun 2023; 689:149238. [PMID: 37979329 DOI: 10.1016/j.bbrc.2023.149238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 11/08/2023] [Accepted: 11/08/2023] [Indexed: 11/20/2023]
Abstract
UBE2T is an E2 ubiquitin ligase critical for ubiquitination of substrate and plays important roles in many diseases. Despite the important function, UBE2T is considered as an undruggable target due to lack of a pocket for binding to small molecules with satisfied properties for clinical applications. To develop potent and specific UBE2T inhibitors, we adopted a high-throughput screening assay and two compounds-ETC-6152 and ETC-9004 containing a sulfone tetrazole scaffold were identified. Solution NMR study demonstrated the direct interactions between UBE2T and compounds in solution. Further co-crystal structures reveal the binding modes of these compounds. Both compound hydrolysation and formation of a hydrogen bond with the thiol group of the catalytic cysteine were observed. The formation of covalent complex was confirmed with mass spectrometry. As these two compounds inhibit ubiquitin transfer, our study provides a strategy to develop potent inhibitors of UBE2T.
Collapse
Affiliation(s)
- Jothi Anantharajan
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Qian Wen Tan
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Justina Fulwood
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Wang Sifang
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Qiwei Huang
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Hui Qi Ng
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Xiaoying Koh
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Weijun Xu
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Joseph Cherian
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore
| | - Nithya Baburajendran
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore.
| | - CongBao Kang
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore.
| | - Zhiyuan Ke
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #5-01, 138670, Singapore.
| |
Collapse
|
4
|
Huang Q, Ng HQ, Loh YY, Ke Z, Lim WH, Kang C. Backbone 1H, 15N and 13C resonance assignments for an E2 ubiquitin conjugating enzyme-UBE2T. Biomol NMR Assign 2023; 17:269-274. [PMID: 37773242 DOI: 10.1007/s12104-023-10154-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 09/20/2023] [Indexed: 10/01/2023]
Abstract
Ubiquitin-conjugating enzyme E2 T (UBE2T) plays important roles in ubiquitination of proteins through participation in transferring ubiquitin to its substrate. Due to its importance in protein modifications, UBE2T associates with diverse diseases and serves as an important target for drug discovery and development. The crystal structure of UBE2T has been determined and the structure reveals the lack of a druggable pocket for binding to small molecules for clinical applications. Despite the challenge, effort has been made to develop UBE2T inhibitors. We obtained UBE2T constructs with and without the C-terminal region which is flexible in solution. Herein, we report the backbone resonance assignments for human UBE2T without the C-terminal region. The backbone dynamics of UBE2T was also explored. The available assignments will be helpful for hit identification, determining ligand binding site and understanding the mechanism of action of UBE2T inhibitors.
Collapse
Affiliation(s)
- Qiwei Huang
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore, 138670, Singapore
| | - Hui Qi Ng
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore, 138670, Singapore
| | - Yong Yao Loh
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore, 138670, Singapore
| | - Zhiyuan Ke
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore, 138670, Singapore
| | - Wan Hsin Lim
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore, 138670, Singapore
| | - CongBao Kang
- Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, #05-01, Singapore, 138670, Singapore.
| |
Collapse
|
5
|
Hong S, Su Z, Li J, Yu S, Lin B, Ke Z, Zhang Q, Guo Z, Lv W, Peng S, Cheng L, He Q, Liu R, Xiao H. 307P Development of circulating free DNA methylation markers for thyroid nodule diagnostics. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
6
|
Xie P, Li F, Zhao S, Li Q, Liu J, Lu K, Zhang Y, Li T, Zhou J, Ke Z, Chen X. LB959 Lesion location for melanoma pathology analysis. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.05.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Hong S, Li J, Cheng L, Yu S, Zhang Z, Lin B, Su Z, Ke Z, Liu R, Peng S, Li Q, Zhang Q, Guo Z, Lv W, Xiao H. Classification of thyroid nodule using DNA methylation profiling on tissue and circulating tumor DNA. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz267.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Huang C, Liew SS, Lin GR, Poulsen A, Ang MJY, Chia BCS, Chew SY, Kwek ZP, Wee JLK, Ong EH, Retna P, Baburajendran N, Li R, Yu W, Koh-Stenta X, Ngo A, Manesh S, Fulwood J, Ke Z, Chung HH, Sepramaniam S, Chew XH, Dinie N, Lee MA, Chew YS, Low CB, Pendharkar V, Manoharan V, Vuddagiri S, Sangthongpitag K, Joy J, Matter A, Hill J, Keller TH, Foo K. Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3". ACS Med Chem Lett 2019; 10:1240. [PMID: 31413812 DOI: 10.1021/acsmedchemlett.9b00278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
[This corrects the article DOI: 10.1021/acsmedchemlett.9b00170.].
Collapse
|
9
|
Huang C, Liew SS, Lin GR, Poulsen A, Ang MJY, Chia BCS, Chew SY, Kwek ZP, Wee JLK, Ong EH, Retna P, Baburajendran N, Li R, Yu W, Koh-Stenta X, Ngo A, Manesh S, Fulwood J, Ke Z, Chung HH, Sepramaniam S, Chew XH, Dinie N, Lee MA, Chew YS, Low CB, Pendharkar V, Manoharan V, Vuddagiri S, Sangthongpitag K, Joy J, Matter A, Hill J, Keller TH, Foo K. Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3. ACS Med Chem Lett 2019; 10:978-984. [PMID: 31223458 DOI: 10.1021/acsmedchemlett.9b00170] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Accepted: 05/23/2019] [Indexed: 11/28/2022] Open
Abstract
SMYD3 is a histone methyltransferase that regulates gene transcription, and its overexpression is associated with multiple human cancers. A novel class of tetrahydroacridine compounds which inhibit SMYD3 through a covalent mechanism of action is identified. Optimization of these irreversible inhibitors resulted in the discovery of 4-chloroquinolines, a new class of covalent warheads. Tool compound 29 exhibits high potency by inhibiting SMYD3's enzymatic activity and showing antiproliferative activity against HepG2 in 3D cell culture. Our findings suggest that covalent inhibition of SMYD3 may have an impact on SMYD3 biology by affecting expression levels, and this warrants further exploration.
Collapse
Affiliation(s)
- Chuhui Huang
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Si Si Liew
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Grace R. Lin
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Anders Poulsen
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Melgious J. Y. Ang
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Brian C. S. Chia
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Sin Yin Chew
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Zekui P. Kwek
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - John L. K. Wee
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Esther H. Ong
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Priya Retna
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Nithya Baburajendran
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Rong Li
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Weixuan Yu
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Xiaoying Koh-Stenta
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Anna Ngo
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Sravanthy Manesh
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Justina Fulwood
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Zhiyuan Ke
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Hwa Hwa Chung
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | | | - Xin Hui Chew
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Nurul Dinie
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - May Ann Lee
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Yun Shan Chew
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Choon Bing Low
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Vishal Pendharkar
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Vithya Manoharan
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Susmitha Vuddagiri
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Kanda Sangthongpitag
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Joma Joy
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Alex Matter
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Jeffrey Hill
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Thomas H. Keller
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| | - Klement Foo
- Experimental Drug Development Centre, 10 Biopolis Road #05-01 Chromos, Singapore 138670
| |
Collapse
|
10
|
Madan B, Ke Z, Lei ZD, Oliver FA, Oshima M, Lee MA, Rozen S, Virshup DM. NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition. Oncotarget 2017; 7:12386-92. [PMID: 26848981 PMCID: PMC4914292 DOI: 10.18632/oncotarget.7157] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2015] [Accepted: 01/23/2016] [Indexed: 01/16/2023] Open
Abstract
Activation of Wnt signaling due to Wnt overexpression or mutations of Wnt pathway components is associated with various cancers. Blocking Wnt secretion by inhibiting PORCN enzymatic activity has shown efficacy in a subset of cancers with elevated Wnt signaling. Predicting response to upstream Wnt inhibitors and monitoring response to therapeutics is challenging due to the paucity of well-defined biomarkers. In this study we identify Notum as a potential biomarker for Wnt driven cancers and show that coordinate regulation of NOTUM and AXIN2 expression may be a useful predictor of response to PORCN inhibitors. Most importantly, as NOTUM is a secreted protein and its levels in blood correlate with tumor growth, it has potential as a pharmacodynamic biomarker for PORCN and other Wnt pathway inhibitors.
Collapse
Affiliation(s)
- Babita Madan
- Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
| | - Zhiyuan Ke
- Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore
| | - Zheng Deng Lei
- Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
| | | | - Masanobu Oshima
- Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan
| | - May Ann Lee
- Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore
| | - Steve Rozen
- Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore
| | - David M Virshup
- Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore.,Department of Pediatrics, Duke University, Durham, NC, USA
| |
Collapse
|
11
|
Ho SY, Alam J, Jeyaraj DA, Wang W, Lin GR, Ang SH, Tan ESW, Lee MA, Ke Z, Madan B, Virshup DM, Ding LJ, Manoharan V, Chew YS, Low CB, Pendharkar V, Sangthongpitag K, Hill J, Keller TH, Poulsen A. Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors. J Med Chem 2017; 60:6678-6692. [PMID: 28671458 DOI: 10.1021/acs.jmedchem.7b00662] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.
Collapse
Affiliation(s)
- Soo Yei Ho
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Jenefer Alam
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | | | - Weiling Wang
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Grace Ruiting Lin
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Shi Hua Ang
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Eldwin Sum Wai Tan
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - May Ann Lee
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Zhiyuan Ke
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Babita Madan
- Duke-NUS Graduate Medical School Singapore , 8 College Road, 169857, Singapore
| | - David M Virshup
- Duke-NUS Graduate Medical School Singapore , 8 College Road, 169857, Singapore
| | - Li Jun Ding
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Vithya Manoharan
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Yun Shan Chew
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Choon Bing Low
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Vishal Pendharkar
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Kanda Sangthongpitag
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Jeffrey Hill
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Thomas H Keller
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Anders Poulsen
- Experimental Therapeutics Centre , 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| |
Collapse
|
12
|
Ke Z, Wang S, Manoharan V, Vuddagiri S, Ong E, Lim S, Ong ST, Sangthongpitag K, Kassoum N, Hill J, Lee MA. Abstract 3819: Identification and quantification of isoforms of eukaryotic initiation factor 4E as biomarker in Mnk inhibitor-treated mouse model by capillary-based immunoassay platform. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-3819] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Elevated levels of the phosphorylated m7G cap binding protein, eukaryotic initiation factor 4E (eIF4E) are associated with neoplasia. An observed oncogenic signaling effect upon activation of Erk1/2 or p38 MAPKs in cells is the phosphorylation of eIF4E specifically at Serine 209 by downstream kinase MAP kinase-interacting kinase 1 and 2 (Mnks). Therefore, inhibiting Mnks could be a potential therapeutic approach that selectively targets cancer cells without introducing toxicity to normal cells. To measure the target engagement and efficacy of Mnk inhibitors, we have established a sensitive method to quantitatively detect phospho-eIF4E and non-phospho-eIF4E. Here, we report using NanoPro 100 system, an automated capillary-based immunoassay platform that could separate the phosphorylated and non-phosphorylated eIF4E isoforms based on different isoelectric points. Primary antibodies against both non-phospho eIF4E and Serine 209 phosphorylated eIF4E were used for identification and verification of eIF4E isoforms in protein samples obtained from cell lysate, blood samples and tumor samples. Two major isoforms of eIF4E with isoelectric point at 5.38 for phospho-eIF4E and 5.88 for non-phospho-eIF4E were identified in eIF4E-overexpressing K562 cells. siRNA knockdown of eIF4E expression reduced both isoforms, while treatment with Mnk inhibitor only reduced phospho-eIF4E level. The measurement and quantification of the relative changes of phosphorylated eIF4E by this method can potentially be used in monitoring the efficacy of Mnk inhibitors in xenograft and future clinical trials.
Citation Format: Zhiyuan Ke, Sifang Wang, Vithya Manoharan, Susmitha Vuddagiri, Esther Ong, Sharon Lim, Sin Tiong Ong, Kanda Sangthongpitag, Nacro Kassoum, Jeffrey Hill, May Ann Lee. Identification and quantification of isoforms of eukaryotic initiation factor 4E as biomarker in Mnk inhibitor-treated mouse model by capillary-based immunoassay platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3819. doi:10.1158/1538-7445.AM2017-3819
Collapse
Affiliation(s)
- Zhiyuan Ke
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Sifang Wang
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Vithya Manoharan
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Susmitha Vuddagiri
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Esther Ong
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Sharon Lim
- 2Duke-NUS Medical School, Singapore, Singapore
| | | | - Kanda Sangthongpitag
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Nacro Kassoum
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Jeffrey Hill
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - May Ann Lee
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| |
Collapse
|
13
|
Loibl S, Demichele A, Turner N, Cristofanilli M, Loi S, Verma S, Bhattacharyya H, Ke Z, Giorgetti C, Bartlett C, Iyer S, Colleoni M, Masuda N, Im SA, Harbeck N. Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2- metastatic breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.39] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Madan B, Ke Z, Harmston N, Petretto E, Hill J, Keller TH, Lee MA, Matter A, Virshup DM. Abstract B13: ETC-159 is a novel PORCN inhibitor effective for treatment of Wnt-addicted genetically defined cancers. Mol Cancer Res 2016. [DOI: 10.1158/1557-3125.devbiolca15-b13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Pathologic expression of Wnts is found in cancers, fibrosis and other diseases, hence there is considerable interest in blocking Wnt signaling to achieve therapeutic benefit. Post-translational palmitoleation of Wnts at a highly conserved serine residue is essential for their secretion and function. We have pursued a strategy to block all Wnt-dependent pathways concomitantly using a small molecule inhibitor of the enzyme PORCN that is required for Wnt O-palmitoleation. As Wnt pathway inhibitors advance to clinical trials, the paucity of well-defined biomarkers makes it challenging to monitor response to therapeutics.
We have developed a novel PORCN inhibitor ETC-159, which has remarkable efficacy in pre-clinical models of RNF43-mutant pancreatic and ovarian cancers and RSPO3-translocation bearing colorectal cancer patient derived xenografts. ETC-159 reverses Wnt dependent pathology by promoting cellular differentiation. Consistent with the role of Wnt/β-catenin signaling in regulation of diverse cellular functions, RNA sequencing of these ETC-159 sensitive, Wnt driven cancers has revealed significant remodeling of the transcriptome on treatment with ETC-159 with a decrease of cell cycle, stem cell, and proliferation genes and an increase in differentiation markers. Our studies show that coordinate regulation of NOTUM and AXIN2 gene expression may be a useful predictor of sensitivity to PORCN inhibitors. NOTUM is a secreted protein and its levels in serum correlate with tumor growth. Notum has potential to be a pharmacodynamic biomarker that will reflect a response to PORCN and other Wnt pathway inhibitors.
Citation Format: Babita Madan, Zhiyuan Ke, Nathan Harmston, Enrico Petretto, Jeffrey Hill, Thomas H. Keller, May Ann Lee, Alex Matter, David M. Virshup. ETC-159 is a novel PORCN inhibitor effective for treatment of Wnt-addicted genetically defined cancers. [abstract]. In: Proceedings of the AACR Special Conference: Developmental Biology and Cancer; Nov 30-Dec 3, 2015; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(4_Suppl):Abstract nr B13.
Collapse
Affiliation(s)
- Babita Madan
- 1Duke-NUS Graduate Medical School, Singapore, Singapore,
| | - Zhiyuan Ke
- 2Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore, Singapore
| | | | | | - Jeffrey Hill
- 2Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore, Singapore
| | - Thomas H. Keller
- 2Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore, Singapore
| | - May Ann Lee
- 2Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore, Singapore
| | - Alex Matter
- 2Experimental Therapeutics Centre, A*STAR, Biopolis, Singapore, Singapore
| | | |
Collapse
|
15
|
Ke Z, Zhu Z, Xu Z, Fang C, Hu S. Formulation Design and In vitro Evaluation of Berberine- Loaded Self-Nanoemulsifying Drug Delivery System. TROP J PHARM RES 2015. [DOI: 10.4314/tjpr.v14i5.1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
16
|
Xu H, Li J, Ke Z, Huang H. Dysregulation of SGK1 in the endometrium causes endometrial receptivity defects and embryo implantation failure in diabetes. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.530] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Ke Z, Madan B, Lim SQ, Wang S, Alam J, Ho SY, Jeyaraj DA, Ghosh K, Chew YS, Ding LJ, Monoharan V, Pendharkar V, Ong E, Hill J, Sangthongpitag K, Keller T, Lee MA, Virshup DM. Abstract 4449: A novel Porcupine inhibitor is effective in the treatment of cancers with RNF43 mutations. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Various mutations in the Wnt pathway contribute to aberrant activation of Wnt signaling, which is implicated in multiple cancers. Besides the mutation of Adenomatous polyposis coli (APC) or beta-catenin which causes the continuous activation of Wnt signaling by stabilizing beta-catenin, there are mutations of other genes such as RNF43 that regulate Wnt signaling at the level of the ligand or cell surface receptor. Inhibition of the secretion of all human Wnts by blocking their palmitoleoylation by the O-acyltransferase, Porcupine (PORCN), could be an alternative therapeutic approach. Here we have developed a compound with a novel pharmacophore that can inhibit PORCN activity and hence Wnt signaling in nanomolar concentration. In vivo efficacy study demonstrated that the compound is highly efficacious in preventing tumor growth in genetic modification model MMTV-WNT1 mouse. We have identified a subset of pancreatic cancer, cholangiocarcinoma and mucinous ovarian cancer cell lines that are sensitive to the compound. Most of these cell lines harbor mutations in RNF43. Xenograft tumor models derived from the cancer cell lines were found to be sensitive to the compound. Our results demonstrate that inhibiting the Wnt/beta-catenin pathway by targeting PORCN with small-molecule inhibitors in a subset of cancers with mutation in RNF43 is a feasible and nontoxic strategy to overcome the problem of redundancy of Wnts, thereby, providing new option for therapy in diseases with up regulated Wnt expression.
Citation Format: Zhiyuan Ke, Babita Madan, Shermaine Q.y. Lim, Sifang Wang, Jenefer Alam, Soo Yei Ho, Duraiswamy Athisayamani Jeyaraj, Kakaly Ghosh, Yun Shan Chew, Li Jun Ding, Vithya Monoharan, Vishal Pendharkar, Esther Ong, Jeffrey Hill, Kanda Sangthongpitag, Thomas Keller, May Ann Lee, David M. Virshup. A novel Porcupine inhibitor is effective in the treatment of cancers with RNF43 mutations. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4449. doi:10.1158/1538-7445.AM2015-4449
Collapse
Affiliation(s)
- Zhiyuan Ke
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Babita Madan
- 2Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore
| | - Shermaine Q.y. Lim
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Sifang Wang
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Jenefer Alam
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Soo Yei Ho
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | | | - Kakaly Ghosh
- 2Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore
| | - Yun Shan Chew
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Li Jun Ding
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Vithya Monoharan
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Vishal Pendharkar
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Esther Ong
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Jeffrey Hill
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Kanda Sangthongpitag
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - Thomas Keller
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - May Ann Lee
- 1Experimental Therapeutics Centre, Agency for Science, Technology and Research, Singapore, Singapore
| | - David M. Virshup
- 2Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore
| |
Collapse
|
18
|
Duraiswamy AJ, Lee MA, Madan B, Ang SH, Tan ESW, Cheong WWV, Ke Z, Pendharkar V, Ding LJ, Chew YS, Manoharan V, Sangthongpitag K, Alam J, Poulsen A, Ho SY, Virshup DM, Keller TH. Discovery and Optimization of a Porcupine Inhibitor. J Med Chem 2015; 58:5889-99. [PMID: 26110200 DOI: 10.1021/acs.jmedchem.5b00507] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Wnt proteins regulate various cellular functions and serve distinct roles in normal development throughout life. Wnt signaling is dysregulated in various diseases including cancers. Porcupine (PORCN) is a membrane-bound O-acyltransferase that palmitoleates the Wnts and hence is essential for their secretion and function. The inhibition of PORCN could serve as a therapeutic approach for the treatment of a number of Wnt-dependent cancers. Herein, we describe the identification of a Wnt secretion inhibitor from cellular high throughput screening. Classical SAR based cellular optimization provided us with a PORCN inhibitor with nanomolar activity and excellent bioavailability that demonstrated efficacy in a Wnt-driven murine tumor model. Finally, we also discovered that enantiomeric PORCN inhibitors show very different activity in our reporter assay, suggesting that such compounds may be useful for mode of action studies on the PORCN O-acyltransferase.
Collapse
Affiliation(s)
| | - May Ann Lee
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Babita Madan
- ‡Duke-NUS Graduate Medical School Singapore, 8 College Road, 169857, Singapore
| | - Shi Hua Ang
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Eldwin Sum Wai Tan
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Wei Wen Vivien Cheong
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Zhiyuan Ke
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Vishal Pendharkar
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Li Jun Ding
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Yun Shan Chew
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Vithya Manoharan
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Kanda Sangthongpitag
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Jenefer Alam
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Anders Poulsen
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - Soo Yei Ho
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| | - David M Virshup
- ‡Duke-NUS Graduate Medical School Singapore, 8 College Road, 169857, Singapore
| | - Thomas H Keller
- †Experimental Therapeutics Centre, 31 Biopolis Way, No. 03-01 Nanos, 138669, Singapore
| |
Collapse
|
19
|
Poulsen A, Ho SY, Wang W, Alam J, Jeyaraj DA, Ang SH, Tan ESW, Lin GR, Cheong VWW, Ke Z, Lee MA, Keller TH. Pharmacophore Model for Wnt/Porcupine Inhibitors and Its Use in Drug Design. J Chem Inf Model 2015; 55:1435-48. [PMID: 26024410 DOI: 10.1021/acs.jcim.5b00159] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Porcupine is a component of the Wnt pathway which regulates cell proliferation, migration, stem cell self-renewal, and differentiation. The Wnt pathway has been shown to be dysregulated in a variety of cancers. Porcupine is a membrane bound O-acyltransferase that palmitoylates Wnt. Inhibiting porcupine blocks the secretion of Wnt and effectively inhibits the Wnt pathway. Using high throughput screening, we have identified a number of novel porcupine inhibitors with diverse scaffolds. The pharmacophore requirements for our porcupine inhibitors were elucidated, and a pharmacophore model is proposed. Our compounds as well as all currently published porcupine inhibitors may be fitted to this model in low energy conformations with good superimposition of the pharmacophore elements. The model also explains the stereochemical requirements of our chiral porcupine inhibitors. The pharmacophore model was successfully used for designing 3 new series of porcupine inhibitors having a tricyclic xantine, a phtalimide, or a piperidine-maleimide scaffold.
Collapse
Affiliation(s)
- Anders Poulsen
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Soo Yei Ho
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Weiling Wang
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Jenefer Alam
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Duraiswamy A Jeyaraj
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Shi Hua Ang
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Eldwin Sum Wai Tan
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Grace Ruiting Lin
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Vivien Wei Wen Cheong
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Zhiyuan Ke
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - May Ann Lee
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| | - Thomas H Keller
- Experimental Therapeutics Centre, Agency for Science, Technology and Research, 31 Biopolis Way, Nanos Level 3, Singapore 138669
| |
Collapse
|
20
|
Gopalan B, Narayanan K, Ke Z, Lu T, Zhang Y, Zhuo L. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma. Biomaterials 2014; 35:7479-87. [PMID: 24912819 DOI: 10.1016/j.biomaterials.2014.05.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 05/08/2014] [Indexed: 11/16/2022]
Abstract
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed lethal cancers in the world. We previously showed two imidazolium salts (IBN-1 and IBN-9) with a moderate efficacy for HCC. Here we report a more potent imidazolium compound IBN-65 (1-benzyl-2-phenyl-3-(4-isopropyl)-benzyl-imidazolium chloride) and the associated mechanisms of action in a mouse model of HCC. The IC50 of this compound in various liver cancer cell lines was around 5 μm. IBN-65 dose-dependently arrested cell cycle at G1 phase and was associated with the down-regulation of the cyclin-dependent kinase-4, -6, cyclin D1, and cyclin E. In addition, IBN-65 induced apoptosis by down-regulating Survivin, Bcl-2 and up-regulating Bax, leading to sequential activation of Caspase-3, Caspase-9 and the cleavage of poly(ADP-ribose) polymerase (PARP). Dysregulation of the epidermal growth factor receptor (EGFR) signaling network has been frequently reported in HCC. We found that IBN-65 displayed a profound inhibitory effect on the EGFR/Raf/MEK/ERK signaling at the phosphorylation level. In Huh7 or Hep3B cells, pretreatment with IBN-65 attenuated EGF-induced phosphorylation of both EGFR and the downstream p44/42 MAPK. A siRNA knockdown of EGFR also proved that IBN-65 induced apoptosis mostly through inhibiting downstream EGFR pathway signaling, much less at the receptor level. Infrequent administration of IBN-65 (i.p., 5 mg/kg once weekly for four weeks) to mice bearing the Huh7 cells significantly reduced the tumor volume by 65% without affecting the body weight. Critically, many of the anti-tumor signaling features observed in the HCC cell lines were recaptured in the xenografted tissues. Thus, the metal-free imidazolium compound IBN-65 could be a potential candidate towards therapeutic development for HCC.
Collapse
Affiliation(s)
- Began Gopalan
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Biopolis, Singapore 138669, Singapore
| | - Karthikeyan Narayanan
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Biopolis, Singapore 138669, Singapore
| | - Zhiyuan Ke
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Biopolis, Singapore 138669, Singapore
| | - Ting Lu
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Biopolis, Singapore 138669, Singapore
| | - Yugen Zhang
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Biopolis, Singapore 138669, Singapore
| | - Lang Zhuo
- Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Biopolis, Singapore 138669, Singapore; Research and Development Center for Innovative Pharmaceuticals, Guangxi Botanic Garden of Medicinal Plants, Chinese Academy of Medical Sciences, 189 Changgang Road, Nanning, Guangxi 530023, China.
| |
Collapse
|
21
|
Madan B, Ke Z, Lim SQ, Alam J, Ho SY, Jeyaraj DA, Ghosh K, Chew YS, Aliyev J, Ding LJ, Pendharkar V, Wang S, Sangthongpitag K, Keller T, Lee MA, Virshup DM. Abstract C248: Novel PORCN inhibitors are safe and effective in the treatment of WNT-dependent cancers. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-c248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Dysregulation of the Wnt signaling cascades is implicated in multiple disorders. There are 19 human Wnts that mediate signaling through diverse downstream pathways. To achieve maximum benefit from inhibition of Wnt signaling, targeting all of these pathways may be useful. The secretion and biological activity of all human Wnts requires palmitoylation mediated by Porcupine (PORCN), an endoplasmic reticulum-localized membrane bound O-acyltransferase. Several small molecule inhibitors of PORCN have been developed. Here we report a novel pharmacophore with derivatives that are nanomolar inhibitors of Wnt signaling. By a number of criteria, these compounds potently inhibit PORCN catalytic activity and hence suppress downstream Wnt-activated signaling pathways. The compounds effectively reduce autocrine Wnt signaling activity in selected cancer cell lines. The inhibitory activity is stereospecific, as an (R) enantiomer is inactive. Compounds with good oral bioavailability were tested for their in vivo activity and found to be highly efficacious in reversing tumor growth in both MMTV-WNT1 mice and of tumor xenografts. Treated tumors showed marked nuclear exclusion and decreased cytoplasmic staining of beta-catenin compared to vehicle controls. Importantly the treatment modulated downstream markers of Wnt signaling. No signs of toxicity were observed in mice at therapeutically effective doses. These results and our published results on C59 demonstrate that inhibiting the Wnt/beta-catenin pathway by targeting PORCN with small-molecule inhibitors is a feasible and nontoxic strategy. Use of porcupine inhibitors overcomes the problem of redundancy of Wnts, thereby, providing new options for therapy in diseases with high Wnt activity.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):C248.
Citation Format: Babita Madan, Zhiyuan Ke, Shermaine Q.y. Lim, Jenefer Alam, Soo Yei Ho, Duraiswamy A. Jeyaraj, Kakaly Ghosh, Yun Shan Chew, Jamal Aliyev, Li Jun Ding, Vishal Pendharkar, Sifang Wang, Kanda Sangthongpitag, Thomas Keller, May Ann Lee, David M. Virshup. Novel PORCN inhibitors are safe and effective in the treatment of WNT-dependent cancers. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr C248.
Collapse
Affiliation(s)
- Babita Madan
- 1Duke-NUS Graduate Medical School, Singapore, Singapore
| | - Zhiyuan Ke
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | | | - Jenefer Alam
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | - Soo Yei Ho
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | | | - Kakaly Ghosh
- 1Duke-NUS Graduate Medical School, Singapore, Singapore
| | - Yun Shan Chew
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | - Jamal Aliyev
- 1Duke-NUS Graduate Medical School, Singapore, Singapore
| | - Li Jun Ding
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | | | - Sifang Wang
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | | | - Thomas Keller
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | - May Ann Lee
- 2Experimental Therapeutics Center, A*STAR, Singapore, Singapore
| | | |
Collapse
|
22
|
Yuan H, Liu H, Tai W, Wang F, Zhang Y, Yao S, Ran T, Lu S, Ke Z, Xiong X, Xu J, Chen Y, Lu T. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling. SAR QSAR Environ Res 2013; 24:795-817. [PMID: 23941641 DOI: 10.1080/1062936x.2013.815655] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Cyclin-dependent kinase 2 (CDK2) has been identified as an important target for developing novel anticancer agents. Molecular docking, three-dimensional quantitative structure-activity relationship (3D-QSAR) and pharmacophore modelling were combined with the ultimate goal of studying the structure-activity relationship of CDK2 inhibitors. The comparative molecular similarity indices analysis (CoMSIA) model constructed based on a set of 3-aminopyrazole derivatives as CDK2 inhibitors gave statistically significant results (q (2) = 0.700; r (2) = 0.982). A HypoGen pharmacophore model, constructed using diverse CDK2 inhibitors, also showed significant statistics ([Formula: see text]Cost = 61.483; RMSD = 0.53; Correlation coefficient = 0.98). The small residues and error values between the estimated and experimental activities of the training and test set compounds proved their strong capability of activity prediction. The structural insights obtained from these two models were consistent with each other. The pharmacophore model summarized the important pharmacophoric features required for protein-ligand binding. The 3D contour maps in combination with the comprehensive pharmacophoric features helped to better interpret the structure-activity relationship. The results will be beneficial for the discovery and design of novel CDK2 inhibitors. The simplicity of this approach provides expansion to its applicability in optimizing other classes of small molecular CDK2 inhibitors.
Collapse
Affiliation(s)
- H Yuan
- a Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University , Nanjing , China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Rao N, Ke Z, Liu H, Ho CJ, Kumar S, Xiang W, Zhu Y, Ge R. ADAMTS4 and its proteolytic fragments differentially affect melanoma growth and angiogenesis in mice. Int J Cancer 2013; 133:294-306. [DOI: 10.1002/ijc.28037] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Affiliation(s)
- Nithya Rao
- Department of Biological Sciences; Faculty of Science, National University of Singapore; Singapore; Singapore
| | - Zhiyuan Ke
- Department of Biological Sciences; Faculty of Science, National University of Singapore; Singapore; Singapore
| | - Hongrui Liu
- Department of Pharmacology; School of Pharmacy, Fudan University; Shanghai; People's Republic of China
| | - Chao-Jin Ho
- Department of Biological Sciences; Faculty of Science, National University of Singapore; Singapore; Singapore
| | - Saran Kumar
- Department of Biological Sciences; Faculty of Science, National University of Singapore; Singapore; Singapore
| | - Wei Xiang
- Department of Biological Sciences; Faculty of Science, National University of Singapore; Singapore; Singapore
| | - Yizhun Zhu
- Department of Pharmacology; School of Pharmacy, Fudan University; Shanghai; People's Republic of China
| | - Ruowen Ge
- Department of Biological Sciences; Faculty of Science, National University of Singapore; Singapore; Singapore
| |
Collapse
|
24
|
Liang K, Ke Z, Chen L, Nie M, Cheng Y, Deng Z. Scaphoid nonunion reconstructed with vascularized bone-grafting pedicled on 1,2 intercompartmental supraretinacular artery and external fixation. Eur Rev Med Pharmacol Sci 2013; 17:1447-1454. [PMID: 23771533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Vascularized bone-grafting pedicled on 1,2 intercompartmental supraretinacular artery (1,2 ICSRA) has been recommended as a treatment alternative for established scaphoid nonunion complicated with proximal pole avascular necrosis (AVN). Previous reports focused the studies on the union rate and the revascularization of the transferred graft. However, the postoperative wrist stiffness still a challenging problem and remaining to be solved. The purpose of our study was to determine whether the combination of vascularized bone-grafting pedicled on 1,2 ICSRA and wrist external fixator immobilization provides a more effective strategy for treating established scaphoid nonunion complicated with AVN and improving postoperative range of motion (ROM) of the injured wrist. PATIENTS AND METHODS We retrospectively reviewed a consecutive series of 11 patients who had cases of established scaphoid nonunion involving AVN of the proximal pole were treated with vascularized bone-grafting pedicled on 1,2 1,2 ICSRA, internal fixation, and wrist external fixator immobilization. Procedure of wrist arthrolysis was performed before vascularized bone graft transferring. Preoperative and postoperative evaluation included measurement of clinical (wrist ROM and grip strength), radiographic (intrascaphoid angle, scapholunate angle) and functional (Mayo wrist score) parameters. RESULTS Osseous union was achieved in all of the 11 cases within an average period of 11.4 weeks. On an average 6.1 years follow-up, there were three excellent, six good and two fair results. Significant improvements were found for Mayo wrist score, wrist ROM, and grip strength (p < 0.01). Intrascaphoid angle and scapholunate angle were significantly improved postoperatively, and there was no significant difference between the postoperative values and the values at the last follow-up. Early functional rehabilitation of the injured wrist under the protection of the fixator did not result in displacement of the transferred graft. CONCLUSIONS The results of the present investigation support the use of the vascularized bone graft pedicled on 1,2 ICSRA in the treatment of scaphoid nonunion complicated with proximal pole AVN. Procedures of wrist arthrolysis and early institution of wrist functional rehabilitation under the protection of the external fixator play important role in the restoration of range of motion of the injured wrist.
Collapse
Affiliation(s)
- K Liang
- Orthopaedic Department, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China.
| | | | | | | | | | | |
Collapse
|
25
|
Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, Hannoush RN, Virshup DM. Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer. Cancer Res 2012. [PMID: 23188502 DOI: 10.1158/0008-5472.can-12-2258] [Citation(s) in RCA: 278] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Porcupine (PORCN) is a membrane bound O-acyltransferase that is required for Wnt palmitoylation, secretion, and biologic activity. All evaluable human Wnts require PORCN for their activity, suggesting that inhibition of PORCN could be an effective treatment for cancers dependent on excess Wnt activity. In this study, we evaluated the PORCN inhibitor Wnt-C59 (C59), to determine its activity and toxicity in cultured cells and mice. C59 inhibits PORCN activity in vitro at nanomolar concentrations, as assessed by inhibition of Wnt palmitoylation, Wnt interaction with the carrier protein Wntless/WLS, Wnt secretion, and Wnt activation of β-catenin reporter activity. In mice, C59 displayed good bioavailability, as once daily oral administration was sufficient to maintain blood concentrations well above the IC(50). C59 blocked progression of mammary tumors in MMTV-WNT1 transgenic mice while downregulating Wnt/β-catenin target genes. Surprisingly, mice exhibit no apparent toxicity, such that at a therapeutically effective dose there were no pathologic changes in the gut or other tissues. These results offer preclinical proof-of-concept that inhibiting mammalian Wnts can be achieved by targeting PORCN with small-molecule inhibitors such as C59, and that this is a safe and feasible strategy in vivo.
Collapse
Affiliation(s)
- Kyle David Proffitt
- Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Ke Z, Lim S, Wang S, Fulwood J, Proffitt K, Madan B, Choong M, Flotow H, Virshup D, Lee M. 172 Identification of Small Molecule Inhibitors of Wnt Secretion. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71970-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Abstract
Several lysosomal cathepsins have been implicated in a number of diseases, from arthritis to cancer. A recent member of the cathepsin family, cathepsin S (Cat S) has been associated with several types of cancer in humans. However, to date, no report has linked Cat S to human hepatocellular carcinoma (HCC). Here, we investigated the expression of Cat S in human normal and HCC livers using immunohistochemistry and Western blot analysis. The results showed that no expression or very low levels of Cat S expression were detected in the hepatocytes of normal livers. In contrast, a significant increase in Cat S expression was detected in the cancerous hepatocytes in 34 of the total 63 HCC livers (54%; P<0.01). The Cat S-positive rate was significantly higher in the HCC nodule than in the perinodular region (P<0.01). Nevertheless, the Cat S-positive rate in the peri-HCC region was still significantly higher than that in the normal liver tissue (P<0.01). Elevated Cat S expression in HCC was positively correlated with the presence of portal vein tumor thrombus (P<0.01), extra-hepatic metastasis (P<0.05) and the degree of de-differentiation (P<0.01), but was not correlated with age, the presence of hepatitis B virus surface antigen and cirrhosis, the level of serum α-fetoprotein, the number of tumor nodules, the tumor size and the clinical stage (P>0.05). Aberrant overexpression of Cat S in the cancerous hepatocytes may be one of the key events involved in HCC tumorigenesis, invasion and metastasis.
Collapse
Affiliation(s)
- Jing Xu
- The First Affiliated Hospital of Guangxi Medical University, Guangxi 530021, P.R. China
| | | | | | | | | | | |
Collapse
|
28
|
Xiang W, Ke Z, Zhang Y, Cheng GHY, Irwan ID, Sulochana KN, Potturi P, Wang Z, Yang H, Wang J, Zhuo L, Kini RM, Ge R. Isthmin is a novel secreted angiogenesis inhibitor that inhibits tumour growth in mice. J Cell Mol Med 2012; 15:359-74. [PMID: 19874420 PMCID: PMC3822802 DOI: 10.1111/j.1582-4934.2009.00961.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Anti-angiogenesis represents a promising therapeutic strategy for the treatment of various malignancies. Isthmin (ISM) is a gene highly expressed in the isthmus of the midbrain–hindbrain organizer in Xenopus with no known functions. It encodes a secreted 60 kD protein containing a thrombospondin type 1 repeat domain in the central region and an adhesion-associated domain in MUC4 and other proteins (AMOP) domain at the C-terminal. In this work, we demonstrate that ISM is a novel angiogenesis inhibitor. Recombinant mouse ISM inhibited endothelial cell (EC) capillary network formation on Matrigel through its C-terminal AMOP domain. It also suppressed vascular endothelial growth factor (VEGF)-basic fibroblast growth factor (bFGF) induced in vivo angiogenesis in mouse. It mitigated VEGF-stimulated EC proliferation without affecting EC migration. Furthermore, ISM induced EC apoptosis in the presence of VEGF through a caspase-dependent pathway. ISM binds to αvβ5 integrin on EC surface and supports EC adhesion. Overexpression of ISM significantly suppressed mouse B16 melanoma tumour growth through inhibition of tumour angiogenesis without affecting tumour cell proliferation. Knockdown of isthmin in zebrafish embryos using morpholino antisense oligonucleotides led to disorganized intersegmen-tal vessels in the trunk. Our results demonstrate that ISM is a novel endogenous angiogenesis inhibitor with functions likely in physiological as well as pathological angiogenesis.
Collapse
Affiliation(s)
- Wei Xiang
- Department of Biological Sciences, National University of Singapore, Singapore
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Ke Z, Jianjun L, Fu Q, Qiang W. The value of 320-sl ice dynamic volume MDCT on In-stent restenosis in patients with coronary stent implantation. Heart 2011. [DOI: 10.1136/heartjnl-2011-300867.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Chen W, Ke Z, Shi H, Yang S, Wang L. Overexpression of AEG-1 in renal cell carcinoma and its correlation with tumor nuclear grade and progression. Neoplasma 2010; 57:522-9. [PMID: 20845990 DOI: 10.4149/neo_2010_06_522] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED The study was aimed at detecting the expression of a newly found oncogene, astrocyte elevated gene-1 (AEG-1), in renal cell carcinoma (RCC) and its correlation with histopathologic features and the survival of patients. Real-time reverse transcription-PCR and Western blot showed markedly higher expression of AEG-1 in 8 cases of RCC tissue compared with the paired normal tissue from the same patient. The expression level of AEG-1 was also increased in four RCC cell lines in contrast with normal tubular epithelial human kidney cells 2 (HK-2) at both mRNA and protein levels. Furthermore, immunohistochemistry analysis showed highly expressed AEG-1 in 96 of 102 (94.1%) cases of paraffin-embedded archival RCC tissue. Statistical analysis showed a significant correlation of AEG-1 expression with tumor grade (P <0.001), clinical staging (P = 0.003), T classification (P = 0.003) as well as metastasis classification (P=0.032). The means for survival time of low AEG-1 expression group was 76.98m<br />while high AEG-1expression group was 60.94m. Our results suggest that AEG-1 protein is overexpressed in RCC and plays an important role in tumor differentiation and progression. <br />High AEG-1 expression is closely associated with poor prognosis. KEYWORDS Astrocyte elevated gene-1, AEG-1, renal cell carcinoma, prognosis.
Collapse
Affiliation(s)
- W Chen
- Department of Pathology, Sun Yat-sen University, Guangzhou, China
| | | | | | | | | |
Collapse
|
31
|
Ho G, Kumar S, Ke Z, Chan HHN, Suhaimi NAM, Kng YL, Zhang Y, Zhuo L. Imidazolium salt (DBZIM) reduces gliosis in mice treated with neurotoxicant 2'-CH(3) -MPTP. CNS Neurosci Ther 2010; 17:148-57. [PMID: 20406246 DOI: 10.1111/j.1755-5949.2009.00131.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
We have recently identified a class of imidazolium salts (IMSs) with antioxidative property and can function as scavengers for radical oxygen species (ROS) [18]. Here, we investigate one of the IMSs, 1,3-bisbenzylimidazolium bromide (DBZIM), for its possible role in attenuating neurotoxicity and gliosis in the retina and the brain induced by a Parkinsonian neurtoxicant, methyl-4(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH(3) -MPTP), which is a free radical generating agent. In this study, we employ a molecular retinal imaging method, which we recently developed in a transgenic mouse model expressing green fluorescent protein (GFP) under the control of glial fibrillary acidic protein (GFAP) promoter [14], to assess the efficacy of DBZIM, since currently no in vitro system with a sufficient complexity is available for accurately assessing a compound's efficacy. The longitudinal imaging results showed DBZIM can effectively suppress the neurotoxicant-induced retinal gliosis. Immunohistochemistry performed on the postmodern mouse brain confirmed that DBZIM also reduced striatal gliosis, and concomitantly attenuated the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). These findings suggest that DBZIM could be a useful small molecular compound for studying neurotoxicity and neuroprotection in the retina and the brain.
Collapse
Affiliation(s)
- Gideon Ho
- Institute of Bioengineering and Nanotechnology, Singapore
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Xu G, Xiong Z, Yong Y, Wang Z, Ke Z, Xia Z, Hu Y. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum. Neuroscience 2010; 167:174-84. [PMID: 20123001 DOI: 10.1016/j.neuroscience.2010.01.048] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2009] [Revised: 01/18/2010] [Accepted: 01/23/2010] [Indexed: 11/16/2022]
Abstract
The protective effect of an iridoid catalpol extracted and purified from the traditional Chinese medicinal herb Rehmannia glutinosa on the neuronal degeneration of nigral-striatal dopaminergic pathway was studied in a chronic 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP)/probenecid C57BL/6 mouse model and in 1-methyl-4-phenylpyridimium (MPP(+)) intoxicated cultured mesencephalic neurons. Rotarod performance revealed that the locomotor ability of mice was significantly impaired after completion of model production and maintained thereafter for at least 4 weeks. Catalpol orally administered for 8 weeks (starting from the second week of model production) dose dependently improved the locomotor ability. HPLC revealed that catalpol significantly elevated striatal dopamine levels without changing the metabolite/dopamine ratios. Nor did it bind to dopamine receptors. Therefore it is unlikely that catalpol resembles any of the known compounds for treating Parkinsonism. Instead, catalpol dose dependently raised the tyrosine hydroxylase (TH) neuron number in substantia nigra pars compacta (SNpc), the striatal dopamine transporter (DAT) density and the striatal glial cell derived neurotrophic factor (GDNF) protein level. Linear regression revealed that both the TH neuron number and DAT density were positively correlated to the GDNF level. In the cultured mesencephalic neurons, MPP(+) decreased the dopaminergic neuron number and shortened the neurite length, whereas catalpol showed protective effect dose dependently. Furthermore, the expression of GDNF mRNA was up-regulated by catalpol to a peak nearly double of normal control in neurons intoxicated with MPP(+) for 24 h but not in normal neurons. The GDNF receptor tyrosine kinase RET inhibitor 4-amino-5-(4-methyphenyl)-7-(t-butyl)-pyrazolo-[3,4-d]pyrimidine (PP1) abolished the protective effect of catalpol either partially (TH positive neuron number) or completely (neurite length). Taken together, catalpol improves locomotor ability by attenuating the neuronal degeneration of nigral-striatal dopaminergic pathway, and this attenuation is at least partially through elevating the striatal GDNF expression.
Collapse
Affiliation(s)
- G Xu
- Research Laboratory of Cell Regulation, Shanghai Jiaotong University School of Medicine, Shanghai, PR China
| | | | | | | | | | | | | |
Collapse
|
33
|
Ke Z, Zhang X, Ma L, Wang L. Expression of DPC4/Smad4 in non-small-cell lung carcinoma and its relationship with angiogenesis. Neoplasma 2008; 55:323-329. [PMID: 18505344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The DPC4 influences tumourigenesis and tumor progression by various mechanisms, including angiogenesis. The aim of this study was to determine whether the expression of DPC4 is related to the angiogenesis in lung cancer and whether it could be involved in its clinical behaviour. Immunohistochemistry revealed that DPC4 was expressed at high level in normal broncho-tracheal epithelium, but at low level in tumor tissues, and closely correlated with tumor lymph node metastasis. This result was further confirmed by Western blot analysis. Furthermore, carcinomas with high DPC4 expression demonstrated low VEGF expression and low MVD (microvessel density) labelled with CD34. In addition, DPC4 siRNA in A549 cells also showed that DPC4 could decrease VEGF protein and mRNA expression, and increase TSP1 protein and mRNA expression. Our findings indicated that DPC4 might be an important biomarker for malignant transformation and be involved in preventing the tumor metastasis by inhibiting tumor angiogenesis.
Collapse
Affiliation(s)
- Z Ke
- Department of Pathology, Medical School of Sun Yat-sen University, Guangzhou, Province, Guandong, China
| | | | | | | |
Collapse
|
34
|
An L, Hu J, Yang M, Jin F, Du Q, Ke Z. Enhanced vitellogenin induction of secondary effluents by chlorination. Bull Environ Contam Toxicol 2006; 77:67-73. [PMID: 16832757 DOI: 10.1007/s00128-006-1033-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2005] [Accepted: 05/25/2006] [Indexed: 05/10/2023]
Affiliation(s)
- L An
- State Key Laboratory of Environmental Aquatic Chemistry, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, People's Republic of China
| | | | | | | | | | | |
Collapse
|
35
|
Ke Z, Emelyanov A, Lim SES, Korzh V, Gong Z. Expression of a novel zebrafish zinc finger gene, gli2b, is affected in Hedgehog and Notch signaling related mutants during embryonic development. Dev Dyn 2005; 232:479-86. [PMID: 15614761 DOI: 10.1002/dvdy.20242] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Gli zinc-finger proteins are known as downstream mediators of the evolutionary conserved Hedgehog pathway. In zebrafish, gli2 functions differently from Gli2 in mammals. This difference could be due to the gli2 duplication in teleosts evolution and partial redundancy between two duplicated genes. Here, we report a novel zebrafish gli2-like cDNA. Its structure, genetic location, and distinct expression pattern in the central nervous system suggested that this gene might represent a second gli2 of teleosts, and we named it gli2b. gli2b was expressed in the neural keel, excluding the forebrain-midbrain boundary, while gli2 expression complemented this pattern. After 24 hours postfertilization, several specific domains of gli2b expression were observed in the lateral and medial hindbrain and hypothalamus. In mutants affecting the Hedgehog and Notch signaling pathways, gli2b expression was either disrupted or extended in different regions.
Collapse
Affiliation(s)
- Zhiyuan Ke
- Department of Biological Sciences, National University of Singapore, Singapore 117604
| | | | | | | | | |
Collapse
|
36
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Badaud F, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, Martins CDO, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gay P, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Gris P, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Houben P, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Makovec N, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sumowidagdo S, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Measurement of dijet azimuthal decorrelations at central rapidities in pp collisions at sqrt s =1.96 TeV. Phys Rev Lett 2005; 94:221801. [PMID: 16090381 DOI: 10.1103/physrevlett.94.221801] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/16/2004] [Indexed: 05/03/2023]
Abstract
Correlations in the azimuthal angle between the two largest transverse momentum jets have been measured using the D0 detector in p (-)p collisions at a center-of-mass energy sqrt[s]=1.96 TeV. The analysis is based on an inclusive dijet event sample in the central rapidity region corresponding to an integrated luminosity of 150 pb(-1). Azimuthal correlations are stronger at larger transverse momenta. These are well described in perturbative QCD at next-to-leading order in the strong coupling constant, except at large azimuthal differences where contributions with low transverse momentum are significant.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Search for supersymmetry with gauge-mediated breaking in diphoton events at D0. Phys Rev Lett 2005; 94:041801. [PMID: 15783547 DOI: 10.1103/physrevlett.94.041801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2004] [Indexed: 05/24/2023]
Abstract
We report the results of a search for supersymmetry (SUSY) with gauge-mediated breaking in the missing transverse energy distribution of inclusive diphoton events using 263 pb(-1) of data collected by the D0 experiment at the Fermilab Tevatron Collider in 2002-2004. No excess is observed above the background expected from standard model processes, and lower limits on the masses of the lightest neutralino and chargino of about 108 and 195 GeV, respectively, are set at the 95% confidence level. These are the most stringent limits to date for models with gauge-mediated SUSY breaking with a short-lived neutralino as the next-to-lightest SUSY particle.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anastasoaie M, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Atramentov O, Autermann C, Avila C, Babukhadia L, Bacon TC, Badaud F, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Bellavance A, Beri SB, Bernardi G, Bernhard R, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Blessing S, Bloch D, Blumenschein U, Boehnlein A, Boeriu O, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchanan NJ, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément B, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooke M, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisher W, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gay P, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Gris P, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Harrington R, Hauptman JM, Hauser R, Hays C, Hays J, Hebbeker T, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Houben P, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev VM, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipaev VV, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magerkurth A, Magnan AM, Maity M, Makovec N, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pogorelov Y, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin AA, Schwartzman A, Schwienhorst R, Sengupta S, Severini H, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Skubic P, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Spurlock B, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sumowidagdo S, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev IA, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Von Vlimant JR, Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, Wermes N, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yan M, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Measurement of the B0s lifetime in the exclusive decay channel B0s-->J/psiphi. Phys Rev Lett 2005; 94:042001. [PMID: 15783550 DOI: 10.1103/physrevlett.94.042001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2004] [Indexed: 05/24/2023]
Abstract
Using the exclusive decay B0s-->J/psi(mu+mu-)phi(K+K-), we report the most precise single measurement of the B0s lifetime. The data sample corresponds to an integrated luminosity of approximately 220 pb(-1) collected with the D0 detector at the Fermilab Tevatron Collider in 2002-2004. We reconstruct 337 signal candidates, from which we extract the B0s lifetime, tau(B0s)=1.444(+0.098)(-0.090)(stat)+/-0.020(sys) ps. We also report a measurement for the lifetime of the B0 meson using the exclusive decay B0-->J/psi(mu+mu-)K*0(892)(K+pi-). We reconstruct 1370 signal candidates, obtaining tau(B0)=1.473(+0.052)(-0.050)(stat)+/-0.023(sys) ps, and the ratio of lifetimes, tau(B0s)/tau(B0)=0.980(+0.076)(-0.071)(stat)+/-0.003(sys).
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Beri SB, Bernardi G, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Hauptman JM, Hauser R, Hays C, Hays J, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev V, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Mättig P, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin A, Schwartzman A, Schwienhorst R, Sengupta S, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Tully C, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev I, Vaupel M, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Observation and properties of the X(3872) decaying to J/psipi(+)pi(-) in pp collisions at sqrt[s]=1.96 TeV. Phys Rev Lett 2004; 93:162002. [PMID: 15524981 DOI: 10.1103/physrevlett.93.162002] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2004] [Indexed: 05/24/2023]
Abstract
We report the observation of the X(3872) in the J/psipi(+)pi(-) channel, with J/psi decaying to mu(+)mu(-), in pp collisions at sqrt[s]=1.96 TeV. Using approximately 230 pb(-1) of data collected with the Run II D0 detector, we observe 522+/-100 X(3872) candidates. The mass difference between the X(3872) state and the J/psi is measured to be 774.9+/-3.1(stat)+/-3.0(syst) MeV/c(2). We have investigated the production and decay characteristics of the X(3872) and find them to be similar to those of the psi(2S) state.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abazov VM, Abbott B, Abolins M, Acharya BS, Adams DL, Adams M, Adams T, Agelou M, Agram JL, Ahmed SN, Ahn SH, Alexeev GD, Alkhazov G, Alton A, Alverson G, Alves GA, Anderson S, Andrieu B, Arnoud Y, Askew A, Asman B, Autermann C, Avila C, Babukhadia L, Bacon TC, Baden A, Baffioni S, Baldin B, Balm PW, Banerjee S, Barberis E, Bargassa P, Baringer P, Barnes C, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beauceron S, Beaudette F, Begel M, Beri SB, Bernardi G, Bertram I, Besançon M, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Binder M, Bischoff A, Black KM, Blackler I, Blazey G, Blekman F, Bloch D, Blumenschein U, Boehnlein A, Bolton TA, Bonamy P, Borcherding F, Borissov G, Bos K, Bose T, Boswell C, Brandt A, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burdin S, Burnett TH, Busato E, Butler JM, Bystricky J, Canelli F, Carvalho W, Casey BCK, Casey D, Cason NM, Castilla-Valdez H, Chakrabarti S, Chakraborty D, Chan KM, Chandra A, Chapin D, Charles F, Cheu E, Chevalier L, Cho DK, Choi S, Chopra S, Christiansen T, Christofek L, Claes D, Clark AR, Clément C, Coadou Y, Colling DJ, Coney L, Connolly B, Cooper WE, Coppage D, Corcoran M, Coss J, Cothenet A, Cousinou MC, Crépé-Renaudin S, Cristetiu M, Cummings MAC, Cutts D, da Motta H, Davies B, Davies G, Davis GA, De K, de Jong P, de Jong SJ, De La Cruz-Burelo E, De Oliveira Martins C, Dean S, Del Signore K, Déliot F, Delsart PA, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doidge M, Dong H, Doulas S, Duflot L, Dugad SR, Duperrin A, Dyer J, Dyshkant A, Eads M, Edmunds D, Edwards T, Ellison J, Elmsheuser J, Eltzroth JT, Elvira VD, Eno S, Ermolov P, Eroshin OV, Estrada J, Evans D, Evans H, Evdokimov A, Evdokimov VN, Fast J, Fatakia SN, Fein D, Feligioni L, Ferbel T, Fiedler F, Filthaut F, Fisk HE, Fleuret F, Fortner M, Fox H, Freeman W, Fu S, Fuess S, Galea CF, Gallas E, Galyaev E, Gao M, Garcia C, Garcia-Bellido A, Gardner J, Gavrilov V, Gelé D, Gelhaus R, Genser K, Gerber CE, Gershtein Y, Geurkov G, Ginther G, Goldmann K, Golling T, Gómez B, Gounder K, Goussiou A, Graham G, Grannis PD, Greder S, Green JA, Greenlee H, Greenwood ZD, Gregores EM, Grinstein S, Grivaz JF, Groer L, Grünendahl S, Grünewald MW, Gu W, Gurzhiev SN, Gutierrez G, Gutierrez P, Haas A, Hadley NJ, Haggerty H, Hagopian S, Hall I, Hall RE, Han C, Han L, Hanagaki K, Hanlet P, Harder K, Hauptman JM, Hauser R, Hays C, Hays J, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Hensel C, Hesketh G, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Hohlfeld M, Hong SJ, Hooper R, Hou S, Hu Y, Huang J, Huang Y, Iashvili I, Illingworth R, Ito AS, Jabeen S, Jaffré M, Jain S, Jain V, Jakobs K, Jenkins A, Jesik R, Jiang Y, Johns K, Johnson M, Johnson P, Jonckheere A, Jonsson P, Jöstlein H, Juste A, Kado MM, Käfer D, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Kalk J, Karmanov D, Kasper J, Kau D, Ke Z, Kehoe R, Kermiche S, Kesisoglou S, Khanov A, Kharchilava A, Kharzheev YM, Kim KH, Klima B, Klute M, Kohli JM, Kopal M, Korablev V, Kotcher J, Kothari B, Kotwal AV, Koubarovsky A, Kouchner A, Kouznetsov O, Kozelov AV, Kozminski J, Krane J, Krishnaswamy MR, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kurca T, Kuznetsov VE, Lager S, Lahrichi N, Landsberg G, Lazoflores J, Le Bihan AC, Lebrun P, Lee SW, Lee WM, Leflat A, Leggett C, Lehner F, Leonidopoulos C, Lewis P, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipton R, Lobo L, Lobodenko A, Lokajicek M, Lounis A, Lu J, Lubatti HJ, Lucotte A, Lueking L, Luo C, Lynker M, Lyon AL, Maciel AKA, Madaras RJ, Magnan AM, Maity M, Mal PK, Malik S, Malyshev VL, Manankov V, Mao HS, Maravin Y, Marshall T, Martens M, Martin MI, Mattingly SEK, Mayorov AA, McCarthy R, McCroskey R, McMahon T, Meder D, Melanson HL, Melnitchouk A, Meng X, Merkin M, Merritt KW, Meyer A, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mitrevski J, Mokhov N, Molina J, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Muanza GS, Mulders M, Mutaf YD, Nagy E, Nang F, Narain M, Narasimham VS, Naumann NA, Neal HA, Negret JP, Nelson S, Neustroev P, Noeding C, Nomerotski A, Novaes SF, Nunnemann T, Nurse E, O'Dell V, O'Neil DC, Oguri V, Oliveira N, Olivier B, Oshima N, Otero y Garzón GJ, Padley P, Papageorgiou K, Parashar N, Park J, Park SK, Parsons J, Partridge R, Parua N, Patwa A, Perea PM, Perez E, Peters O, Pétroff P, Petteni M, Phaf L, Piegaia R, Podesta-Lerma PLM, Podstavkov VM, Pope BG, Popkov E, Prado da Silva WL, Prosper HB, Protopopescu S, Przybycien MB, Qian J, Quadt A, Quinn B, Rani KJ, Rapidis PA, Ratoff PN, Reay NW, Renardy JF, Reucroft S, Rha J, Ridel M, Rijssenbeek M, Ripp-Baudot I, Rizatdinova F, Royon C, Rubinov P, Ruchti R, Sabirov BM, Sajot G, Sánchez-Hernández A, Sanders MP, Santoro A, Savage G, Sawyer L, Scanlon T, Schamberger RD, Schellman H, Schieferdecker P, Schmitt C, Schukin A, Schwartzman A, Schwienhorst R, Sengupta S, Shabalina E, Shary V, Shephard WD, Shpakov D, Sidwell RA, Simak V, Sirotenko V, Skow D, Slattery P, Smith RP, Smolek K, Snow GR, Snow J, Snyder S, Söldner-Rembold S, Song X, Song Y, Sonnenschein L, Sopczak A, Sorín V, Sosebee M, Soustruznik K, Souza M, Stanton NR, Stark J, Steele J, Steinbrück G, Stevenson K, Stolin V, Stone A, Stoyanova DA, Strandberg J, Strang MA, Strauss M, Ströhmer R, Strovink M, Stutte L, Sznajder A, Talby M, Tamburello P, Taylor W, Telford P, Temple J, Tentindo-Repond S, Thomas E, Thooris B, Tomoto M, Toole T, Torborg J, Towers S, Trefzger T, Trincaz-Duvoid S, Trippe TG, Tuchming B, Turcot AS, Tuts PM, Uvarov L, Uvarov S, Uzunyan S, Vachon B, Van Kooten R, van Leeuwen WM, Varelas N, Varnes EW, Vasilyev I, Verdier P, Vertogradov LS, Verzocchi M, Villeneuve-Seguier F, Vlimant JR, Von Toerne E, Vreeswijk M, Vu Anh T, Wahl HD, Walker R, Wallace N, Wang ZM, Warchol J, Warsinsky M, Watts G, Wayne M, Weber M, Weerts H, Wegner M, White A, White V, Whiteson D, Wicke D, Wijngaarden DA, Wilson GW, Wimpenny SJ, Wittlin J, Wlodek T, Wobisch M, Womersley J, Wood DR, Wu Z, Wyatt TR, Xu Q, Xuan N, Yamada R, Yasuda T, Yatsunenko YA, Yen Y, Yip K, Youn SW, Yu J, Yurkewicz A, Zabi A, Zatserklyaniy A, Zdrazil M, Zeitnitz C, Zhang B, Zhang D, Zhang X, Zhao T, Zhao Z, Zheng H, Zhou B, Zhou Z, Zhu J, Zielinski M, Zieminska D, Zieminski A, Zitoun R, Zutshi V, Zverev EG, Zylberstejn A. Search for doubly charged higgs boson pair production in the decay to mu(+)mu(+)mu(-)mu(-) in pp collisions at sqrt[s]=1.96 TeV. Phys Rev Lett 2004; 93:141801. [PMID: 15524781 DOI: 10.1103/physrevlett.93.141801] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2004] [Indexed: 05/24/2023]
Abstract
A search for pair production of doubly charged Higgs bosons in the process pp -->H(++)H(--) -->mu(+)mu(+)mu(-)mu(-) is performed with the D0 run II detector at the Fermilab Tevatron. The analysis is based on a sample of inclusive dimuon data collected at an energy of sqrt[s]=1.96 TeV, corresponding to an integrated luminosity of 113 pb(-1). In the absence of a signal, 95% confidence level mass limits of M(H(+/-+/-)(L))>118.4 GeV/c(2) and M(H(+/-+/-)(R))>98.2 GeV/c(2) are set for left-handed and right-handed doubly charged Higgs bosons, respectively, assuming 100% branching into muon pairs.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
BACKGROUND Urinary calculi is a common condition characterized of high incidence and high recurrence rate. For a long time, increased water intake has been the main preventive measure for the disease and its recurrence. OBJECTIVES To access the effectiveness of increased water intake for the primary and secondary prevention of urinary calculi. SEARCH STRATEGY Relevant RCTs were identified by electronic and documental searches of MEDLINE, EMBASE, the Chinese Biomedical Disk and the Cochrane Central Register of Controlled Trials. No language restriction was applied. Date of last search: May 2004. SELECTION CRITERIA Randomised controlled trials (RCTs) and quasi-RCTs of increased water intake for the prevention of urinary calculi and its recurrence. DATA COLLECTION AND ANALYSIS Two reviewers independently assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes or weight mean difference (WMD) for continuous data with 95% confidence intervals (CI). MAIN RESULTS No trials of increased water intake for the primary prevention of urinary calculi met the inclusion criteria. One trial with 199 patients provided results of increased water intake for the recurrence of urinary calculi. The recurrence rate was lower in the increased water intake group than that of the no intervention group (12% versus 27%, P = 0.008, RR = 0.45, 95% CI 0.24 to 0.84). The average interval for recurrences was 3.23 +/-1.1 years in increased water intake group and 2.09 +/- 1.37 years in the no intervention group (P = 0.016, WMD = 1.14, 95% CI 0.33 to 1.95). REVIEWERS' CONCLUSIONS The evidence from only one trial indicates that increased water intake reduces the risk of recurrence of urinary calculi and prolongs the average interval for recurrences. However further research is required. Due to the lack of appropriate RCTs, no conclusions can be drawn on increased water intake for the primary and secondary prevention of urinary calculi.
Collapse
|
42
|
Abazov VM, Abbott B, Abdesselam A, Abolins M, Abramov V, Acharya BS, Adams DL, Adams M, Ahmed SN, Alexeev GD, Alves GA, Amos N, Anderson EW, Arnoud Y, Baarmand MM, Babintsev VV, Babukhadia L, Bacon TC, Baden A, Baldin B, Balm PW, Banerjee S, Barberis E, Baringer P, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Beaudette F, Begel M, Belyaev A, Beri SB, Bernardi G, Bertram I, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Blazey G, Blessing S, Boehnlein A, Bojko NI, Borcherding F, Bos K, Brandt A, Breedon R, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burtovoi VS, Butler JM, Canelli F, Carvalho W, Casey D, Casilum Z, Castilla-Valdez H, Chakraborty D, Chan KM, Chekulaev SV, Cho DK, Choi S, Chopra S, Christenson JH, Chung M, Claes D, Clark AR, Cochran J, Coney L, Connolly B, Cooper WE, Coppage D, Crépé-Renaudin S, Cummings MAC, Cutts D, Davis GA, Davis K, De K, De Jong SJ, Del Signore K, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Doulas S, Ducros Y, Dudko LV, Duensing S, Duflot L, Dugad SR, Duperrin A, Dyshkant A, Edmunds D, Ellison J, Elvira VD, Engelmann R, Eno S, Eppley G, Ermolov P, Eroshin OV, Estrada J, Evans H, Evdokimov VN, Fahland T, Feher S, Fein D, Ferbel T, Filthaut F, Fisk HE, Fisyak Y, Flattum E, Fleuret F, Fortner M, Fox H, Frame KC, Fu S, Fuess S, Gallas E, Galyaev AN, Gao M, Gavrilov V, Genik RJ, Genser K, Gerber CE, Gershtein Y, Gilmartin R, Ginther G, Gómez B, Gómez G, Goncharov PI, González Solís JL, Gordon H, Goss LT, Gounder K, Goussiou A, Graf N, Graham G, Grannis PD, Green JA, Greenlee H, Greenwood ZD, Grinstein S, Groer L, Grünendahl S, Gupta A, Gurzhiev SN, Gutierrez G, Gutierrez P, Hadley NJ, Haggerty H, Hagopian S, Hagopian V, Hall RE, Hanlet P, Hansen S, Hauptman JM, Hays C, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Heuring T, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Huang Y, Illingworth R, Ito AS, Jaffré M, Jain S, Jesik R, Johns K, Johnson M, Jonckheere A, Jones M, Jöstlein H, Juste A, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Karmanov D, Karmgard D, Ke Z, Kehoe R, Khanov A, Kharchilava A, Kim SK, Klima B, Knuteson B, Ko W, Kohli JM, Kostritskiy AV, Kotcher J, Kothari B, Kotwal AV, Kozelov AV, Kozlovsky EA, Krane J, Krishnaswamy MR, Krivkova P, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kuznetsov VE, Landsberg G, Lee WM, Leflat A, Leggett C, Lehner F, Li J, Li QZ, Li X, Lima JGR, Lincoln D, Linn SL, Linnemann J, Lipton R, Lucotte A, Lueking L, Lundstedt C, Luo C, Maciel AKA, Madaras RJ, Malyshev VL, Manankov V, Mao HS, Marshall T, Martin MI, Mauritz KM, May B, Mayorov AA, McCarthy R, McMahon T, Melanson HL, Merkin M, Merritt KW, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mokhov N, Mondal NK, Montgomery HE, Moore RW, Mostafa M, Da Motta H, Nagy E, Nang F, Narain M, Narasimham VS, Neal HA, Negret JP, Negroni S, Nomerotski A, Nunnemann T, O'Neil D, Oguri V, Olivier B, Oshima N, Padley P, Pan LJ, Papageorgiou K, Para A, Parashar N, Partridge R, Parua N, Paterno M, Patwa A, Pawlik B, Perkins J, Peters M, Peters O, Pétroff P, Piegaia R, Pope BG, Popkov E, Prosper HB, Protopopescu S, Qian J, Raja R, Rajagopalan S, Ramberg E, Rapidis PA, Reay NW, Reucroft S, Ridel M, Rijssenbeek M, Rizatdinova F, Rockwell T, Roco M, Royon C, Rubinov P, Ruchti R, Rutherfoord J, Sabirov BM, Sajot G, Santoro A, Sawyer L, Schamberger RD, Schellman H, Schwartzman A, Sen N, Shabalina E, Shivpuri RK, Shpakov D, Shupe M, Sidwell RA, Simak V, Singh H, Singh JB, Sirotenko V, Slattery P, Smith E, Smith RP, Snihur R, Snow GR, Snow J, Snyder S, Solomon J, Sorín V, Sosebee M, Sotnikova N, Soustruznik K, Souza M, Stanton NR, Steinbrück G, Stephens RW, Stichelbaut F, Stoker D, Stolin V, Stone A, Stoyanova DA, Strauss M, Strovink M, Stutte L, Sznajder A, Talby M, Taylor W, Tentindo-Repond S, Tripathi SM, Trippe TG, Turcot AS, Tuts PM, Vaniev V, Van Kooten R, Varelas N, Vertogradov LS, Villeneuve-Seguier F, Volkov AA, Vorobiev AP, Wahl HD, Wang H, Wang ZM, Warchol J, Watts G, Wayne M, Weerts H, White A, White JT, Whiteson D, Wightman JA, Wijngaarden DA, Willis S, Wimpenny SJ, Womersley J, Wood DR, Xu Q, Yamada R, Yamin P, Yasuda T, Yatsunenko YA, Yip K, Youssef S, Yu J, Yu Z, Zanabria M, Zhang X, Zheng H, Zhou B, Zhou Z, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG, Zylberstejn A. Search for the scalar top quark in pp collisions at square root[s] = 1.8 TeV. Phys Rev Lett 2002; 88:171802. [PMID: 12005745 DOI: 10.1103/physrevlett.88.171802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2001] [Indexed: 05/23/2023]
Abstract
We have performed a search for scalar top quark (stop) pair production in the inclusive electron-muon-missing transverse energy final state, using a sample of pp events corresponding to 108.3 pb(-1) of data collected with the D0 detector at Fermilab. The search is done in the framework of the minimal supersymmetric standard model assuming that the sneutrino is the lightest supersymmetric particle. For the dominant decays of the lightest stop, t-->b chi+1 and t-->blnu, no evidence for signal is found. We derive cross-section limits as a function of stop ( t ), chargino ( chi+1), and sneutrino ( nu) masses.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abazov VM, Abbott B, Abdesselam A, Abolins M, Abramov V, Acharya BS, Adams DL, Adams M, Ahmed SN, Alexeev GD, Alves GA, Amos N, Anderson EW, Arnoud Y, Baarmand MM, Babintsev VV, Babukhadia L, Bacon TC, Baden A, Baldin B, Balm PW, Banerjee S, Barberis E, Baringer P, Barreto J, Bartlett JF, Bassler U, Bauer D, Bean A, Begel M, Belyaev A, Beri SB, Bernardi G, Bertram I, Besson A, Beuselinck R, Bezzubov VA, Bhat PC, Bhatnagar V, Bhattacharjee M, Blazey G, Blessing S, Boehnlein A, Bojko NI, Borcherding F, Bos K, Brandt A, Breedon R, Briskin G, Brock R, Brooijmans G, Bross A, Buchholz D, Buehler M, Buescher V, Burtovoi VS, Butler JM, Canelli F, Carvalho W, Casey D, Casilum Z, Castilla-Valdez H, Chakraborty D, Chan KM, Chekulaev SV, Cho DK, Choi S, Chopra S, Christenson JH, Chung M, Claes D, Clark AR, Cochran J, Coney L, Connolly B, Cooper WE, Coppage D, Crépé-Renaudin S, Cummings MA, Cutts D, Davis GA, Davis K, De K, de Jong SJ, Del Signore K, Demarteau M, Demina R, Demine P, Denisov D, Denisov SP, Desai S, Diehl HT, Diesburg M, Di Loreto G, Doulas S, Draper P, Ducros Y, Dudko LV, Duensing S, Duflot L, Dugad SR, Duperrin A, Dyshkant A, Edmunds D, Ellison J, Elvira VD, Engelmann R, Eno S, Eppley G, Ermolov P, Eroshin OV, Estrada J, Evans H, Evdokimov VN, Fahland T, Feher S, Fein D, Ferbel T, Filthaut F, Fisk HE, Fisyak Y, Flattum E, Fleuret F, Fortner M, Fox H, Frame KC, Fu S, Fuess S, Gallas E, Galyaev AN, Gao M, Gavrilov V, Genik RJ, Genser K, Gerber CE, Gershtein Y, Gilmartin R, Ginther G, Gómez B, Gómez G, Goncharov PI, González Solís JL, Gordon H, Goss LT, Gounder K, Goussiou A, Graf N, Graham G, Grannis PD, Green JA, Greenlee H, Grinstein S, Groer L, Grünendahl S, Gupta A, Gurzhiev SN, Gutierrez G, Gutierrez P, Hadley NJ, Haggerty H, Hagopian S, Hagopian V, Hall RE, Hanlet P, Hansen S, Hauptman JM, Hays C, Hebert C, Hedin D, Heinmiller JM, Heinson AP, Heintz U, Heuring T, Hildreth MD, Hirosky R, Hobbs JD, Hoeneisen B, Huang Y, Illingworth R, Ito AS, Jaffré M, Jain S, Jesik R, Johns K, Johnson M, Jonckheere A, Jones M, Jöstlein H, Juste A, Kahl W, Kahn S, Kajfasz E, Kalinin AM, Karmanov D, Karmgard D, Ke Z, Kehoe R, Khanov A, Kharchilava A, Kim SK, Klima B, Knuteson B, Ko W, Kohli JM, Kostritskiy AV, Kotcher J, Kothari B, Kotwal AV, Kozelov AV, Kozlovsky EA, Krane J, Krishnaswamy MR, Krivkova P, Krzywdzinski S, Kubantsev M, Kuleshov S, Kulik Y, Kunori S, Kupco A, Kuznetsov VE, Landsberg G, Lee WM, Leflat A, Leggett C, Lehner F, Li J, Li QZ, Li X, Lima JG, Lincoln D, Linn SL, Linnemann J, Lipton R, Lucotte A, Lueking L, Lundstedt C, Luo C, Maciel AK, Madaras RJ, Malyshev VL, Manankov V, Mao HS, Marshall T, Martin MI, Martin RD, Mauritz KM, May B, Mayorov AA, McCarthy R, McMahon T, Melanson HL, Merkin M, Merritt KW, Miao C, Miettinen H, Mihalcea D, Mishra CS, Mokhov N, Mondal NK, Montgomery HE, Moore RW, Mostafa M, da Motta H, Nagy E, Nang F, Narain M, Narasimham VS, Neal HA, Negret JP, Negroni S, Nunnemann T, O'Neil D, Oguri V, Olivier B, Oshima N, Padley P, Pan LJ, Papageorgiou K, Para A, Parashar N, Partridge R, Parua N, Paterno M, Patwa A, Pawlik B, Perkins J, Peters M, Peters O, Pétroff P, Piegaia R, Pope BG, Popkov E, Prosper HB, Protopopescu S, Qian J, Raja R, Rajagopalan S, Ramberg E, Rapidis PA, Reay NW, Reucroft S, Ridel M, Rijssenbeek M, Rizatdinova F, Rockwell T, Roco M, Rubinov P, Ruchti R, Rutherfoord J, Sabirov BM, Sajot G, Santoro A, Sawyer L, Schamberger RD, Schellman H, Schwartzman A, Sen N, Shabalina E, Shivpuri RK, Shpakov D, Shupe M, Sidwell RA, Simak V, Singh H, Singh JB, Sirotenko V, Slattery P, Smith E, Smith RP, Snihur R, Snow GR, Snow J, Snyder S, Solomon J, Sorín V, Sosebee M, Sotnikova N, Soustruznik K, Souza M, Stanton NR, Steinbrück G, Stephens RW, Stichelbaut F, Stoker D, Stolin V, Stone A, Stoyanova DA, Strauss M, Strovink M, Stutte L, Sznajder A, Talby M, Taylor W, Tentindo-Repond S, Tripathi SM, Trippe TG, Turcot AS, Tuts PM, van Gemmeren P, Vaniev V, Van Kooten R, Varelas N, Vertogradov LS, Villeneuve-Seguier F, Volkov AA, Vorobiev AP, Wahl HD, Wang H, Wang ZM, Warchol J, Watts G, Wayne M, Weerts H, White A, White JT, Whiteson D, Wightman JA, Wijngaarden DA, Willis S, Wimpenny SJ, Womersley J, Wood DR, Yamada R, Yamin P, Yasuda T, Yatsunenko YA, Yip K, Youssef S, Yu J, Yu Z, Zanabria M, Zheng H, Zhou Z, Zielinski M, Zieminska D, Zieminski A, Zutshi V, Zverev EG, Zylberstejn A. Search for new physics using QUAERO: a general interface to D0 event data. Phys Rev Lett 2001; 87:231801. [PMID: 11736444 DOI: 10.1103/physrevlett.87.231801] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2001] [Indexed: 05/23/2023]
Abstract
We describe QUAERO, a method that (i) enables the automatic optimization of searches for physics beyond the standard model, and (ii) provides a mechanism for making high energy collider data generally available. We apply QUAERO to searches for standard model WW, ZZ, and t t macro production, to searches for these objects produced through a new heavy resonance, and to the first direct search for W'-->WZ. Through this interface, we make three data sets collected by the D0 experiment at square root of [s] = 1.8 TeV publicly available.
Collapse
Affiliation(s)
- V M Abazov
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH, Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA, Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M, Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington K, Abu-Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R, Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z, Di Francesco V, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z, Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV, Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D, Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang Z, Wang A, Wang X, Wang J, Wei M, Wides R, Xiao C, Yan C, Yao A, Ye J, Zhan M, Zhang W, Zhang H, Zhao Q, Zheng L, Zhong F, Zhong W, Zhu S, Zhao S, Gilbert D, Baumhueter S, Spier G, Carter C, Cravchik A, Woodage T, Ali F, An H, Awe A, Baldwin D, Baden H, Barnstead M, Barrow I, Beeson K, Busam D, Carver A, Center A, Cheng ML, Curry L, Danaher S, Davenport L, Desilets R, Dietz S, Dodson K, Doup L, Ferriera S, Garg N, Gluecksmann A, Hart B, Haynes J, Haynes C, Heiner C, Hladun S, Hostin D, Houck J, Howland T, Ibegwam C, Johnson J, Kalush F, Kline L, Koduru S, Love A, Mann F, May D, McCawley S, McIntosh T, McMullen I, Moy M, Moy L, Murphy B, Nelson K, Pfannkoch C, Pratts E, Puri V, Qureshi H, Reardon M, Rodriguez R, Rogers YH, Romblad D, Ruhfel B, Scott R, Sitter C, Smallwood M, Stewart E, Strong R, Suh E, Thomas R, Tint NN, Tse S, Vech C, Wang G, Wetter J, Williams S, Williams M, Windsor S, Winn-Deen E, Wolfe K, Zaveri J, Zaveri K, Abril JF, Guigó R, Campbell MJ, Sjolander KV, Karlak B, Kejariwal A, Mi H, Lazareva B, Hatton T, Narechania A, Diemer K, Muruganujan A, Guo N, Sato S, Bafna V, Istrail S, Lippert R, Schwartz R, Walenz B, Yooseph S, Allen D, Basu A, Baxendale J, Blick L, Caminha M, Carnes-Stine J, Caulk P, Chiang YH, Coyne M, Dahlke C, Deslattes Mays A, Dombroski M, Donnelly M, Ely D, Esparham S, Fosler C, Gire H, Glanowski S, Glasser K, Glodek A, Gorokhov M, Graham K, Gropman B, Harris M, Heil J, Henderson S, Hoover J, Jennings D, Jordan C, Jordan J, Kasha J, Kagan L, Kraft C, Levitsky A, Lewis M, Liu X, Lopez J, Ma D, Majoros W, McDaniel J, Murphy S, Newman M, Nguyen T, Nguyen N, Nodell M, Pan S, Peck J, Peterson M, Rowe W, Sanders R, Scott J, Simpson M, Smith T, Sprague A, Stockwell T, Turner R, Venter E, Wang M, Wen M, Wu D, Wu M, Xia A, Zandieh A, Zhu X. The sequence of the human genome. Science 2001; 291:1304-51. [PMID: 11181995 DOI: 10.1126/science.1058040] [Citation(s) in RCA: 7678] [Impact Index Per Article: 333.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
A 2.91-billion base pair (bp) consensus sequence of the euchromatic portion of the human genome was generated by the whole-genome shotgun sequencing method. The 14.8-billion bp DNA sequence was generated over 9 months from 27,271,853 high-quality sequence reads (5.11-fold coverage of the genome) from both ends of plasmid clones made from the DNA of five individuals. Two assembly strategies-a whole-genome assembly and a regional chromosome assembly-were used, each combining sequence data from Celera and the publicly funded genome effort. The public data were shredded into 550-bp segments to create a 2.9-fold coverage of those genome regions that had been sequenced, without including biases inherent in the cloning and assembly procedure used by the publicly funded group. This brought the effective coverage in the assemblies to eightfold, reducing the number and size of gaps in the final assembly over what would be obtained with 5.11-fold coverage. The two assembly strategies yielded very similar results that largely agree with independent mapping data. The assemblies effectively cover the euchromatic regions of the human chromosomes. More than 90% of the genome is in scaffold assemblies of 100,000 bp or more, and 25% of the genome is in scaffolds of 10 million bp or larger. Analysis of the genome sequence revealed 26,588 protein-encoding transcripts for which there was strong corroborating evidence and an additional approximately 12,000 computationally derived genes with mouse matches or other weak supporting evidence. Although gene-dense clusters are obvious, almost half the genes are dispersed in low G+C sequence separated by large tracts of apparently noncoding sequence. Only 1.1% of the genome is spanned by exons, whereas 24% is in introns, with 75% of the genome being intergenic DNA. Duplications of segmental blocks, ranging in size up to chromosomal lengths, are abundant throughout the genome and reveal a complex evolutionary history. Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems. DNA sequence comparisons between the consensus sequence and publicly funded genome data provided locations of 2.1 million single-nucleotide polymorphisms (SNPs). A random pair of human haploid genomes differed at a rate of 1 bp per 1250 on average, but there was marked heterogeneity in the level of polymorphism across the genome. Less than 1% of all SNPs resulted in variation in proteins, but the task of determining which SNPs have functional consequences remains an open challenge.
Collapse
Affiliation(s)
- J C Venter
- Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
We investigated the presence of Chlamydia pneumoniae in 81 normal and pathological specimens obtained from postmortem brain tissues of patients with multiple sclerosis and with other neurological or nonneurological diseases. The assays used included PCR amplification of all DNA samples in the initial study. Culture and a second PCR amplification of the organism in a subset of 19 brain specimens were also performed in two separate laboratories. All results were negative. Thus, this study on a large number of brain tissues suggests that C. pneumoniae is not involved in inflammatory demyelination.
Collapse
Affiliation(s)
- M R Hammerschlag
- Chlamydia Research Laboratory, Department of Pediatrics, Division of Infectious Diseases, SUNY Health Science Center at Brooklyn, Brooklyn, New York, USA
| | | | | | | | | | | |
Collapse
|
46
|
Powers TP, Hogan J, Ke Z, Dymbrowski K, Wang X, Collins FH, Kaufman TC. Characterization of the Hox cluster from the mosquito Anopheles gambiae (Diptera: Culicidae). Evol Dev 2000; 2:311-25. [PMID: 11256376 DOI: 10.1046/j.1525-142x.2000.00072.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Hox genes have been found to encode transcription factors, which specify the morphological identity of structures along the anteroposterior axis of animals ranging from worms to mice. The canonical set of nine genes is organized in a cluster in the genome of several protostomes and deuterostomes. However, within insects, whereas the Hox genes are organized in a single cluster in the beetle Tribolium castaneum, they are split into two separate groups in the flies Drosophila melanogaster and Drosophila virilis. The significance of a split Hox cluster is unknown and has been observed in only one organism outside the Drosophila lineage: the nematode Caenorhabditis elegans. We have cloned a majority of the Hox genes from the mosquito Anopheles gambiae (Diptera: Culicidae) and compared their genomic organization with that of Tribolium and Drosophila to determine if a split Hox cluster is found in dipterans aside from the Drosophilidae. We find that the Hox genes in Anopheles, as in Tribolium, are organized in a single cluster that spans a genomic region of at least 700 kb. This finding suggests that, within the insect genome, the partition of the Hox cluster may have evolved exclusively within the Drosophila lineage. The genomic structures of the resident genes, however, appear to be largely conserved between A. gambiae and D. melanogaster.
Collapse
Affiliation(s)
- T P Powers
- Howard Hughes Medical Institute, Department of Biology, Indiana University, Bloomington 47405, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Ke Z, Lu F, Roblin P, Boman J, Hammerschlag MR, Kalman B. Lack of detectable Chlamydia pneumoniae in brain lesions of patients with multiple sclerosis. Ann Neurol 2000; 48:400. [PMID: 10976653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
|
48
|
Ke Z, Zheng C, Qiu M, Shen Y, Hua J. [Laparoscopic gastric resection]. Zhonghua Wai Ke Za Zhi 2000; 38:680-2. [PMID: 11832138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To modify laparoscopic surgery for gastric diseases. METHODS From December 1992 to January 1999, 61 gastric laparoscopic operations were performed in our hospital. The age of the patients ranged from 29 to 78 years (mean 57.4). 17 patients had Billroth II gastrectomy, 1 Billroth I gastrectomy, 2 proximal subtotal gastrectomy, 5 highly selective vagotomy, 3 gastrostomy, and 33 resection of gastric submucosal benign tumor. 54 patients (88.5%) underwent complete laparoscopy, and 7 (11.5%) an assisted one RESULTS The mean operative time was (164.2 +/- 93.5) min, the mean estimated blood loss was (218.3 +/- 166.6) ml, and the mean hospital stay was (6.8 +/- 2.1) days. Flatus was present within 48 hours in 86% of the patients. Two patients had laparoscopic surgery for early gastric cancer, and were followed up for more than 55 months. Postoperative complication were noted in 2 patients, who were cured by reoperation and endoscopy therapy respectively. Only 4 patients required postoperative analgesics. CONCLUSION Although specific indications need to be defined, laparoscopic surgery is feasible. But long-term follow-up should be made to evaluate its efficacy in treatment of gastric cancer.
Collapse
Affiliation(s)
- Z Ke
- Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
| | | | | | | | | |
Collapse
|
49
|
Adams MD, Celniker SE, Holt RA, Evans CA, Gocayne JD, Amanatides PG, Scherer SE, Li PW, Hoskins RA, Galle RF, George RA, Lewis SE, Richards S, Ashburner M, Henderson SN, Sutton GG, Wortman JR, Yandell MD, Zhang Q, Chen LX, Brandon RC, Rogers YH, Blazej RG, Champe M, Pfeiffer BD, Wan KH, Doyle C, Baxter EG, Helt G, Nelson CR, Gabor GL, Abril JF, Agbayani A, An HJ, Andrews-Pfannkoch C, Baldwin D, Ballew RM, Basu A, Baxendale J, Bayraktaroglu L, Beasley EM, Beeson KY, Benos PV, Berman BP, Bhandari D, Bolshakov S, Borkova D, Botchan MR, Bouck J, Brokstein P, Brottier P, Burtis KC, Busam DA, Butler H, Cadieu E, Center A, Chandra I, Cherry JM, Cawley S, Dahlke C, Davenport LB, Davies P, de Pablos B, Delcher A, Deng Z, Mays AD, Dew I, Dietz SM, Dodson K, Doup LE, Downes M, Dugan-Rocha S, Dunkov BC, Dunn P, Durbin KJ, Evangelista CC, Ferraz C, Ferriera S, Fleischmann W, Fosler C, Gabrielian AE, Garg NS, Gelbart WM, Glasser K, Glodek A, Gong F, Gorrell JH, Gu Z, Guan P, Harris M, Harris NL, Harvey D, Heiman TJ, Hernandez JR, Houck J, Hostin D, Houston KA, Howland TJ, Wei MH, Ibegwam C, Jalali M, Kalush F, Karpen GH, Ke Z, Kennison JA, Ketchum KA, Kimmel BE, Kodira CD, Kraft C, Kravitz S, Kulp D, Lai Z, Lasko P, Lei Y, Levitsky AA, Li J, Li Z, Liang Y, Lin X, Liu X, Mattei B, McIntosh TC, McLeod MP, McPherson D, Merkulov G, Milshina NV, Mobarry C, Morris J, Moshrefi A, Mount SM, Moy M, Murphy B, Murphy L, Muzny DM, Nelson DL, Nelson DR, Nelson KA, Nixon K, Nusskern DR, Pacleb JM, Palazzolo M, Pittman GS, Pan S, Pollard J, Puri V, Reese MG, Reinert K, Remington K, Saunders RD, Scheeler F, Shen H, Shue BC, Sidén-Kiamos I, Simpson M, Skupski MP, Smith T, Spier E, Spradling AC, Stapleton M, Strong R, Sun E, Svirskas R, Tector C, Turner R, Venter E, Wang AH, Wang X, Wang ZY, Wassarman DA, Weinstock GM, Weissenbach J, Williams SM, Worley KC, Wu D, Yang S, Yao QA, Ye J, Yeh RF, Zaveri JS, Zhan M, Zhang G, Zhao Q, Zheng L, Zheng XH, Zhong FN, Zhong W, Zhou X, Zhu S, Zhu X, Smith HO, Gibbs RA, Myers EW, Rubin GM, Venter JC. The genome sequence of Drosophila melanogaster. Science 2000; 287:2185-95. [PMID: 10731132 DOI: 10.1126/science.287.5461.2185] [Citation(s) in RCA: 3976] [Impact Index Per Article: 165.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The fly Drosophila melanogaster is one of the most intensively studied organisms in biology and serves as a model system for the investigation of many developmental and cellular processes common to higher eukaryotes, including humans. We have determined the nucleotide sequence of nearly all of the approximately 120-megabase euchromatic portion of the Drosophila genome using a whole-genome shotgun sequencing strategy supported by extensive clone-based sequence and a high-quality bacterial artificial chromosome physical map. Efforts are under way to close the remaining gaps; however, the sequence is of sufficient accuracy and contiguity to be declared substantially complete and to support an initial analysis of genome structure and preliminary gene annotation and interpretation. The genome encodes approximately 13,600 genes, somewhat fewer than the smaller Caenorhabditis elegans genome, but with comparable functional diversity.
Collapse
Affiliation(s)
- M D Adams
- Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Collins FH, Saunders RD, Kafatos FC, Roth C, Ke Z, Wang X, Dymbrowski K, Ton L, Hogan J. Genetics in the study of mosquito susceptibility to Plasmodium. Parassitologia 1999; 41:163-8. [PMID: 10697850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Within the past several years, a number of powerful genetic and genomic tools have been developed for use in research on the African malaria vector Anopheles gambiae. While these tools have been developed with a broad range of potential applications in mind, they have been particularly useful in advancing the effort to clone a set of An. gambiae genes that enable a refractory strain of this mosquito to encapsulate and kill a wide variety of different malaria parasites to which this mosquito is normally fully susceptible. This paper describes the latest progress in this map-based cloning research, which involves the collaborative contributions of a number of different laboratories in Europe and the United States.
Collapse
Affiliation(s)
- F H Collins
- Department of Biological Sciences, University of Notre Dame, IN 46556, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|